These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 7537599)

  • 21. Cardiovascular effects of alpha-blockers for the treatment of symptomatic BPH.
    de Mey C
    Eur Urol; 1998; 34 Suppl 2():18-28; discusion 47. PubMed ID: 9732829
    [No Abstract]   [Full Text] [Related]  

  • 22. Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia?
    Bèïque L; Por CP; Evans MF
    Can Fam Physician; 1998 Dec; 44():2659-62. PubMed ID: 9870119
    [No Abstract]   [Full Text] [Related]  

  • 23. [Urodynamic study of lower urinary tract. VI. Clinical application of alpha adrenergic blocker for the treatment of benign prostatic hypertrophy and bladder neck contracture (author's transl)].
    Kondo A; Narita H; Otani T; Kobayashi M; Takita T
    Nihon Hinyokika Gakkai Zasshi; 1978 Oct; 69(10):1232-40. PubMed ID: 83419
    [No Abstract]   [Full Text] [Related]  

  • 24. Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Elhilali MM
    Expert Opin Pharmacother; 2006 Apr; 7(5):583-96. PubMed ID: 16553574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical efficacy of oxendolene (antiandrogen) and bunazosin hydrochloride (alpha-adrenergic blocker) in the treatment of prostatism--comparative study of oxendolone, bunazocin hydrochloride and their combination].
    Kumamoto Y; Tsukamoto T; Takagi Y; Furuya S; Yokoyama E; Takatsuka K; Tamiya T; Miyamoto S; Aoyama T; Honma A
    Hinyokika Kiyo; 1987 Nov; 33(11):1921-41. PubMed ID: 2451412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
    Lowe FC
    Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of alfuzosine (an alpha 1-adrenoreceptor blocking drug) in benign hyperplasia of the prostate.
    Carbin BE; Bauer P; Friskand M; Moyse D
    Scand J Urol Nephrol Suppl; 1991; 138():73-5. PubMed ID: 1723814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
    McNeill SA; Hargreave TB; Geffriaud-Ricouard C; Santoni J; Roehrborn CG
    Urology; 2001 Mar; 57(3):459-65. PubMed ID: 11248620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effectiveness of various alfuzosin schedules in patients with benign prostatic hyperplasia (BPH)].
    Loran OB; Rasner PI; Kosko D; Pushkar' DIu
    Urologiia; 2001; (1):8-10. PubMed ID: 11233234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A double-blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outflow obstruction.
    Ramsay JW; Scott GI; Whitfield HN
    Br J Urol; 1985 Dec; 57(6):657-9. PubMed ID: 2417649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical study of bunazosin hydrochloride, an alpha 1-adrenergic blocker, in benign prostatic obstruction and neurogenic bladder dysfunction].
    Takita T; Kondo A; Mitsuya H; Otani T
    Hinyokika Kiyo; 1987 Sep; 33(9):1375-84. PubMed ID: 2449057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hormonal therapy of benign prostatic hyperplasia].
    Horninger W; Bartsch G
    Urologe A; 1995 Jan; 34(1):9-15. PubMed ID: 7533450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and pressure-flow changes after long-term treatment with alfuzosin SR.
    De Nunzio C; Franco G; Iori F; Leonardo C; Minardi V; Laurenti C
    Urol Int; 2003; 71(1):31-6. PubMed ID: 12845257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intraoperative floppy iris syndrome in a patient taking alfuzosin for benign prostatic hypertrophy.
    Settas G; Fitt AW
    Eye (Lond); 2006 Dec; 20(12):1431-2. PubMed ID: 16498436
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
    Kirby RS
    Eur Urol; 1998; 33 Suppl 2():19-27. PubMed ID: 9556192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical effect of new alpha-adrenergic blocker on micturition disturbance of neurogenic bladder and lower urinary tract obstruction].
    Takimoto Y; Kitamura K; Fuse T; Kawazoe K; Hirano D; Amagai T; Kiyotaki S
    Hinyokika Kiyo; 1983 Feb; 29(2):255-63. PubMed ID: 6145342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpha-blockers and lower urinary tract function: more than smooth muscle relaxation?
    Michel MC; Schafers RF; Goepel M
    BJU Int; 2000 Oct; 86 Suppl 2():23-8; discussion 28-30. PubMed ID: 11501614
    [No Abstract]   [Full Text] [Related]  

  • 38. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
    Tanaka Y; Masumori N; Itoh N; Sato Y; Takahashi A; Ogura H; Furuya S; Tsukamoto T
    J Urol; 2002 Jun; 167(6):2492-5. PubMed ID: 11992065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Established and upcoming new options in medical therapy for benign prostatic hyperplasia].
    Schlenker B; Beer AM; Gratzke C; Tilki D; Seitz M; Stief CG; Reich O
    MMW Fortschr Med; 2009 Oct; 151(41):33-6. PubMed ID: 19891182
    [No Abstract]   [Full Text] [Related]  

  • 40. [Alfuzosin. A new selective alpha 1 receptor antagonist for symptomatic medical treatment of benign prostatic hypertrophy prior to surgery].
    Hansen BJ; Meyhoff HH
    Ugeskr Laeger; 1992 Feb; 154(6):361-2. PubMed ID: 1371629
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.